Pierre-Francois RouxJohnson and Johnson and Institut Pasteur, Paris"Towards a Systems View of the Senescence Cell Fate »Contact IRCM : Laurent Le Cam

Alejo EfeyanMetabolism and Cell Signalling Group, CNIO, Madrid, Espagne"Nutrient signaling in physiology, cancer and aging"Contact IRCM : Antonio Maraver

Le sang que l’on pensait si bien connaître contiendrait-il en fait des éléments jusque-là indétectables ? C’est ce que montrent les travaux d’une équipe de chercheurs de l’Inserm, de l’Université de Montpellier et de l’Institut du Cancer de Montpellier (ICM) au sein de l’Institut de recherche en cancérologie de Montpellier (IRCM), qui pour la première fois ont mis en évidence la présence dans la circulation sanguine de mitochondries complètes et fonctionnelles. Ces organites responsables de la respiration des cellules n’étaient jusqu’à présent retrouvés hors de ces dernières que dans des cas très particuliers. Ces résultats parus dans The FASEB Journal apportent des connaissances inédites en physiologie et ouvrent la voie à de nouvelles pistes thérapeutiques. Les mitochondries sont des organites situés dans les cellules eucaryotes. Lieu de la respiration cellulaire, elles sont les “batteries” des cellules et jouent un rôle majeur dans le métabolisme énergétique et la communication intercellulaire. Elles ont la particularité de posséder leur propre génome, transmis uniquement par la mère et distinct de l’ADN contenu dans le noyau. Les mitochondries peuvent parfois être observées hors des cellules sous forme de fragments encapsulés dans des microvésicules. Dans certaines conditions très spécifiques les plaquettes sont également capables de libérer des mitochondries intactes dans l’espace extracellulaire.Les travaux d’une équipe de recherche dirigée par le chercheur Inserm Alain R. Thierry à l’Institut de recherche en cancérologie de Montpellier (Inserm/Université de Montpellier/Institut du Cancer de Montpellier) viennent aujourd’hui bouleverser les connaissances sur cet organite, en révélant que des mitochondries extracellulaires, complètes et fonctionnelles, se trouvent en fait en circulation… dans le sang ! Pour en savoir plus : https://presse.inserm.fr/un-nouveau-composant-du-sang-reveleUne interview d'Alain Thierry, co-auteur de l?étude et directeur de recherche à l?Institut de recherche en cancérologie de Montpellier : https://www.rts.ch/play/radio/cqfd/audio/des-mitochondries-decouvertes-dans-le-sang?id=11033620

Céline LENGELLE-KARIBAYE – Annie-Pierre JOINVILLE-BERAService de Pharmacosurveillance - Centre Régional de Pharmacovigilance et d'Information sur le Médicament Centre Val de Loire - Unité de Vigilance des recherches biomédicales CHRU Tours“When interleukin 17 inhibition explain unexpected adverse effects and change safety profile of sécukinumab”Contact Université de tours : Hervé Watier “Secukinumab a monoclonal antibody targeting interleukin (IL) 17-A, is registred in adults for the treatment of plaque psoriasis, psoriatic arthritis and active ankylosing spondylitis. Secukinumab was recently marketed and there is very little data on its safety profile. Based on the biological function of IL-17A, fungal infections were anticipated as a possible side-effect (SE) of secukinumab. The aim of this study was to assess the safety profile of secukinumab and to determine which unexpected SE could be explained by its biological effects. All cases of SE reported with secukinumab to the French Regional Pharmacovigilance Centers or to the firm since marketing (2016) to December 2017, were analyzed. The incidence of SE was estimated using sales of secukinumab. For each type of new SE, a literature review about biological effects of IL 17A was performed. During the 18 months of the study, 690 cases of SE were reported, of which 521 provided useful information: 182 serious and 339 non-serious. The incidence of SE reported was estimated at 4%. Il-17A a T cell-derived proinflammatory cytokine, has been shown to be mostly beneficial against infection caused by extracellular bacteria and fungi. So,the most SE reported were bacterial infections (Staphylococcus, Pneumococcus) (n=48) and Candida infections (n=33). Among digestive SE, Crohn’s disease (CD) (new or exacerbation) (n=15) and ulcerative colitis (n=9) were common. IL-17A plays a role in inflammatory bowel disease but in a study on the treatment of CD, secukinumab demonstrated more relapse than placebo[1]. IL-17 /23 axis is a key player in CD pathogenesis, witch could result from an inappropriate inflammatory response to intestinal microorganisms as C.albicans[2]. Finally, 10 arterial thromboembolisms (myocardial infarction, unstable angina and transient ischemic attack) were reported, always in patients with cardiovascular (CV) risk factors. So, in some trials studying IL17 inhibitors, serious cardiovascular events were more frequent in patients with CR risk factors[3] and IL-17 can have both protective and exacerbating effect on atherosclerosis. Most of new secukinumab SE may be explained by its biological effects. However pharmocoepidemiological studies are needed to confirm this fact, because these diseases could be associated with the initial pathology”.

Maria AbadCellular Plasticity and Cancer, Vall d'Hebron Institute of Oncology, Barcelone, Espagne “When the non-coding codes: exploring the microproteome to find new cancer players”Contact IRCM : Antonio Maraver

22 & 23 june 2020 : 8th Antibody Industrial Symposium « Multispecific Antibodies, Ab-like Molecules and Adoptive Cell Therapy for Fighting Diseases »

At Montpellier, Le Corum

As leaders of the organizing committee and members of the scientific committee, IRCM scientists are proud to share with you the next AIS2020 programme.

Postdoctoral Position in Modeling of the Tumor MicroenvironmentDate limite de candidature : 31/12/2019The Colinge Laboratory Cancer Bioinformatics and Systems Biology at IRCM (Cancer Research Institute of Montpellier) is looking for a talented postdoctoral fellow to work on the evolution of the tumor microenvironment (TME) in response to therapy. This computational work will build upon on-going developments conducted in the lab to infer cellular interactions taking place in the TME. Both single-cell and bulk transcriptomics configurations will be considered. A significant part of the research will relate to lung adenocarcinoma and involve a consortium of expert laboratories in lung cancer and mouse models thereof, animal computer tomography, and 3D imaging. The postdoc position is funded for three years; a 1-year contract will be offered first and extended for another two years based on performance. Preferred qualifications are a bioinformatics Ph.D. with solid computational skills or a mathematics, physics, or computer science Ph.D. with strong interests in life science applications. Interested applicants should e-mail their CV, a letter of motivation, and the names and e-mails of 2 references to Prof Jacques Colinge (at inserm.fr). Applications will be studied immediately. Selected publicationsAlame et al., The molecular landscape and microenvironment of salivary duct carcinoma reveal new therapeutic opportunities, bioRxiv, 2019Lehmann et al., In Vivo Large-Scale Mapping Of Protein Turnover In The Human Cerebrospinal Fluid, bioRxiv, 2019Blomen et al. Gene essentiality and synthetic lethality in haploid human cells. Science, 2015Pichlmair et al. Viral immune modulators perturb the human molecular network by common and unique strategies, Nature, 2012Stukalov et al. Deconvolution of targeted protein-protein interaction maps. J Proteome Res, 2012  

L’Institut de Recherche en Cancérologie de Montpellier a inauguré, le 18 septembre 2019, une plateforme d’imagerie par cytométrie de masse basée sur la technologie CyTOF/Hyperion permettant, pour la première fois en France, de cartographier le microenvironnement cellulaire et l’hétérogénéité tumorale. Cette technologie, unique en France, est porteuse de nouveaux espoirs pour les patients. Elle devrait permettre, à l’heure où l’immunothérapie a des effets cliniques spectaculaires, y compris chez des patients en échappement thérapeutique, d’approfondir la connaissance sur ces nouvelles thérapies anticancéreuses.    Communiqué de presse Inauguration CyTOF IRCM